Current Research Projects

Davis Lab Current Research Projects


Lyden, P., H. Levy, S. Weymer, K. Pryor, W. G. Kramer, J. H. Griffin, T. P. Davis, and B.V. Zlokovic. Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult volunteers. Current Pharmaceutical Design. 19. 2013.

Ronaldson, P.T., and T.P. Davis. Gabapentin and diclofenac reduce opioid consumption in patients undergoing tonsillectomy : A result of altered CNS delivery ? Arch Trauma Res. 2, 2. 97-98. 2013.

Sanchez-Covarrubias, L., Ronaldson P.T. T. W. Vanderah, and T.P. Davis. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac.  PLOS One. In Press. 2013.

Mosnier, L.O., J.A. Fernandez, T.P. Davis, B.V. Zlokovic and J.H. Griffin. Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of tPA and of tPA on the variant’s anticoagulant activity . J Thrombosis Haemostasis. 11, 11. 2059-2062. 2013.

Guo, H., R.D. Bell, S. Wang, A. Sagare, N. Chow, T.P. Davis, J.H. Griffin, S.A. Goldman and B.V. Zlokovic. An activated protein C analog stimulates neuronal production by human neuronal progenitor cells via PAR1-PAR3-S1P-Akt pathway. J. Neuroscience. 33,14. 6181-6190. 2013.

Sanchez-Covarubias, L., T.P. Davis and P.T. Ronaldson. Drug transporters at CNS Barrier Sites:  Obstacle or Opportunity for drug delivery? Current Pharmaceutical Design. June, 19. 2013.

Slosky, L.M., B.J. Thompson, L. Sanchez-Covarubias, Y. Zhang, M. Laracuente, T. W. Vanderah,  P.T. Ronaldson and T. P. Davis. Acetaminophen modulates P- glycoprotein functional expression  at the blood-brain barrier by a constitutive androstane receptor–dependent mechanism. Molecular Pharmacology. 84, 5. 774-786. 2013.

Ronaldson, P.T. and T.P. Davis. Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacological Reviews. 65,1. 291-314. 2013.

Mc Caffrey, G., and T.P. Davis.  Physiology and pathophysiology of the blood brain barrier: p-glycoprotein and occludin trafficking as therapeutic targets to optimize CNS drug delivery. Journal of Investigative Medicine. 60:8. 1131-1140.2012.

Wang, Y., Z. Zhang, N. Chow, T.P. Davis, J.H. Griffin, M. Chopp, and B.V. Zlokovic. An activated protein C analog with reduced anticoagulant activity enhances tPA treatment for ischemic stroke in rodents. Stroke.43:2444-2449.2012.

Ronaldson, P.T. and T. P. Davis. Blood –Brain Barrier Integrity and Glial Support: Mechanisms that can be targeted for novel therapeutic approaches in stroke. Current Pharmaceutical Design. 18,25. 3624-3644. 2012.

Williams, P.D., Zlokovic, B.V., Griffin, J.H., Pryor, K.E., and T. P. Davis. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified Activated Protein C for Ischemic Stroke. Current Pharmaceutical Design.18:4215-4222. 2012.

Mc Caffrey, G., Staatz, W., Ronaldson, P.T., Finch, J.D., DeMarco, K.M., Laracuente, M., and T.P. Davis. P-glycoprotein trafficking at the blood brain barrier altered by peripheral inflammatory hyperalgesia. J. Neurochemistry. 1471-4159.2012.07831.2012.

Ronaldson, P.T. and T.P. Davis. Targeting Blood Brain Barrier Changes during Inflammatory Pain: An Opportunity for Optimizing CNS Drug Delivery. Therapeutic Delivery. 2:1015-1041. 2011

Lochhead, J.J., G. McCaffrey, C. Quigley, J. Finch, K. DeMarco, T.P. Davis and P. T. Ronaldson. Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood brain barrier during inflammatory pain.  Amer. J. of Physiology: Heart and Circ Physiology.  302:H582-H593. 2011.

Ronaldson, P.T., J. D. Finch, K.M. DeMarco, C.M. Solinsky, C. E. Quigley and T.P. Davis. Inflammatory Pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood brain barrier. J. Pharmacology Experimental Therapeutics.  336,3. 827-839.2011.

Lochhead, J. J., G. McCaffrey, C. E. Quigley, J. Finch, K. DeMarco and T.P. Davis. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J. Cerebral Blood Flow and Metabolism. 30,9.1625-1636. 2010.

Willis, C.L., D. S. Meske, and T.P. Davis. Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and post-hypoxic reoxygenation .  J. Cerebral Blood Flow and Metabolism. 30,11. 1847-1859.2010.

Ronaldson, P.T., K.M. DeMarco, L. Sanchez-Covarubias, C.M. Solinsky and T.P. Davis.   Transforming growth factor Beta signaling alters permeability and tight junction protein expression at the blood brain barrier during inflammatory pain.J. Cerebral Blood Flow and Metabolism 29,6. 1084-1098.2009.

Wang, Y., M. Thiyagarajan, N. Chow, I. Singh, H. Guo, T.P. Davis and B. Zlokovic. Differential     Neuroprotection and Risk for Bleeding from Activated Protein C with varying degree of Anticoagulant Activity. Stroke 40, 5. 1864-1869. 2009.

McCaffrey, G.W., C Willis, W. Staatz, N. Nametz, C. Quigley, S. Hom, J. Lochhead and T.P. Davis. Occludin oligomeric assemblies at tight junctions of the blood brain barrier dynamically respond to hypoxia and reoxygenation stress. J. Neurochemistry 110,1:58-71.2009.

McCaffrey, G.W., M.J. Seelbach, W.D. Staatz, N Nametz, C. Quigley, C.R. Campos, T.A. Brooks and T.P. Davis. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J. Neurochemistry.  106(6):2395-2409. 2008.

Brooks, T.A., N. Nametz, R. Charles and T.P. Davis. Diclofenac attenuates the regional effect of
Lambda carrageenan on BBB function and cytoarchitecture. J.Pharmacol Exp.Ther.  2008.

Neuwelt, E., N. Joan Abbott, L.Abrey, W. A. Banks, B. Blakley, T.P. Davis, B. Engelhardt, P. Grammas, M. Nedergard, J. Nutt, W. Pardridge, G. Rosenberg, Q. Smith and L. Drewes.
Strategies to advance translational research into brain barriers.  Lancet Neurology Volume 7, January 2008.

Campos, C.R., S, Hom,  R.D. Egleton and T.P. Davis. Nociceptive inhibition prevents inflammatory pain induced changes in the blood brain barrier. Brain Research (in press).2008.

McCaffrey, G., W. Staatz, R. Egleton, M. Seelbach, C. Campos and T.P. Davis. Tight Junctions contain Oligomeric protein assembly critical for maintaining Blood Brain Barrier integrity in vivo.  J. Neurochemistry 2007.

Seelbach, M.J., J.D. Huber, T. Brooks, R.D. Egleton, K.A. Witt and T.P. Davis. Effect of lambda carrageenan-induced inflammatory pain on brain uptake of morphine and the potential role of P-glycoprotein. J. Neurochemistry . 102,5.1677-1689. 2007. 

Witt, K.A., K.S. Mark , K. Sandoval and T.P. Davis. Reoxygenation stress on Blood Brain Barrier Paracellular Permeability and Edema in the Rat. Microvascular Research doi:10.1016/J.MVR.2007.06.004. 2007.

Hom, S., M.A. Fleegal, R.D. Egleton, C.R. Campos, B. Hawkins  and T.P. Davis. Comparative changes is the blood brain barrier and cerebral infarction of SHR and WKY rats. American Journal of Physiology (Regulatory, Integrative and Comparative Physiology) 292 (5).1881-1892. 2007.

Brooks, T.A.,  C.R. Campos, R.D. Egleton, M. Seelbach, N. Nametz and T.P. Davis. Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Research 1120(1).172-182. 2006.

Witt, K.A. and T.P. Davis. CNS Drug Delivery: Opioid Peptides and the Blood Brain Barrier. The AAPS Journal 7 (4) 9. 2006.

Huber, J.D., C.R. Campos, K.S. Mark and T.P. Davis. Alterations in blood-brain barrier ICAM-1 expression and microglial activation following lambda carrageenan induced inflammatory pain. American Journal of Physiology (Heart and Circulatory) 290(2):H732-740. 2006.

Fleegal, M.A., S. Hom, L.K. Borg and T.P. Davis. Hypoxia and post-hypoxic reoxygenation modulate PKC activity and protein expression in endothelial cells of the blood-brain barrier. American J. Physiology (Heart and Circulatory) 289(5):H2012-2019.2005.

Hawkins, B. T. and T.P. Davis. The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 57(2):173-185, 2005.

Hawkins, B.T., R.D. Egleton and T.P. Davis. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. American J. Physiology (Heart and Circulatory) 289(1): H212-H219. 2005.

Brooks, T.A., B.T. Hawkins, J.D. Huber, R.D. Egleton and T.P. Davis. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. American J. Physiology (Heart and Circulatory) 289(2):H738-H743. 2005.

Egleton, R.D. and T.P. Davis. Development of Neuropeptide Drugs that Cross the Blood- Brain Barrier. NeuroRx.   Jan; 2(1), 44-53. 2005.

Brown, R.C. and T.P. Davis. Hypoxia/Aglycemia alters expression of occludin and actin in brain endothelial cells. Biochemical and Biophysical Research Communications 327(4):1114-1123, 2005.

Witt, K.A., K.S. Mark, J.D. Huber and T.P. Davis. Hypoxia Inducible Factor and Nuclear Factor Kappa-B Activation in Blood Brain Barrier Endothelium under Hypoxic/Reoxygenation Stress. J. Neurochemistry 92(1):203-214, 2005.

Doolittle,N., L.E. Abrey, W. Bleyer, S.Brem, T.P. Davis, P. Dore-Duffy, L. Drewes, W. Hall, J. Hoffman, A. Korfel, R. Martuza, L. Muldoon, D. Peereboom, D. Peterson, S. Rabkin, Q. Smith, G. Stevens and E. A. Neuwelt. New Frontiers in Translational Research in Neuro-Oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood- Brain Barrier Disruption Consortium Meeting. Clinical Cancer Research 11:421-428, 2005.

Hau, V.S., J.D. Huber, C.R. Campos, R.T. Davis and T.P. Davis. Effect of lambda carrageenan induced inflammatory pain on brain uptake of codeine and antinociception. Brain Research 1018(2):257-264, 2004.

Landen, J.W., V. Hau, M. Wang, T.P. Davis, B. Celiax, B.H. Wainer, E.G. Glass, H.C. Joshi and D.R. Archer. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clinical Cancer Research 10(15):5187-5201, 2004.

Hawkins, B.T., T.J. Abbruscato, R.D. Egleton, R.C. Brown, J.D. Huber, C.R. Campos, and T.P. Davis.  Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution.  Brain Research 1027(1-2):48-58, 2004.

Brown, R.C., K.S. Mark and T.P. Davis.  Protection against hypoxia-induced blood brain barrier disruption: Changes in intracellular calcium. American Journal of Physiology- Cell Physiology 286(5):C1045-1052, 2004.

Mark, K.S., A. Burroughs and T.P. Davis.  Nitric oxide mediates hypoxia-induced changes in paracellular permeability of cerebral microvasculature.  American J. Physiology-Heart and Circulatory Physiology 286(1):H174-180, 2004.

Brown, R.C., R.D. Egleton and T.P. Davis.  Mannitol opening of the blood brain barrier: regional variation of sucrose, 86-Rb, or albumin. Brain Research 1014(1-2):221-227, 2004.

Wolka, A., J.D. Huber and T.P. Davis.  Pain and the Blood Brain Barrier: obstacles to drug delivery.  Advanced Drug Delivery Reviews 55(8):987-1006, 2003.

Brown, R.C., K.S. Mark, R.D. Egleton, J.D. Huber, A.R. Burroughs and T.P. Davis.  Protection against hypoxia-induced increase in blood-brain barrier permeability: Role of Tight Junction Proteins and NF kappa B. Journal of Cell Science 116(4):693-700, 2003.

Witt, K.A., K.S. Mark, S. Hom and T.P. Davis.  Effect of Hypoxia/Reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression.  American J. Physiology-Heart and Circulatory Physiology 285(6):H2820-2831, 2003.

Ritchie, J.C., T.P. Davis, and C.B. Nemeroff.   Action of three ectopeptidases on corticotropin-releasing factor: Metabolism and functional aspects. Neuropsychopharmacology 28(1):22-33, 2003.

Egleton, R.D., C.R. Campos, J.D. Huber, R.C. Brown and T.P. Davis.  Differential effects of diabetes on rat choroid plexus ion transporter expression.  Diabetes 52:1496-1501, 2003.

Huber, J.D., R.D. Egleton and T.P. Davis.  Conjugation of low molecular weight polyethylene glycol to biphalin enhances antinociceptive profile.  J. Pharm. Sci. 92:1377-1385, 2003.

Huber, J., V.S. Hau, K.S. Mark, R.C. Brown, C.R. Campos and T.P. Davis. Viability of  microvascular endothelial cells to direct exposure of formalin, lambda-carrageenan and complete Freund’s adjuvant.  European J. Pharmacology 450(3):297-304, 2002.

Witt, K.A. and T.P. Davis. Pluronic P85 block copolymer enhances opioid peptide analgesia.  J. Pharmacol. Exp. Ther. 303(2):760-767, 2002.

Hawkins, B.T., R.C. Brown and T.P. Davis.  Smoking and ischemic stroke: A role for nicotine?  Trends in Pharmacological Sciences 23(2):78-82, 2002.

Huber, J.D., V.S. Hau, C.R. Campos, R.D. Egleton and T.P. Davis.  Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain.  American J. Physiology-Heart and Circulatory Physiology 283(4):H1531-H1537, 2002.

Hau, V., J. Huber, R. Egleton and T.P. Davis.  The effect of guanidino modification and proline substitution on the in vitro stability and BBB permeability of endomorphin II.  J. Pharm. Sci. 91(10):2140-2149. 2002.

Brown, R.C. and T.P. Davis.  Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke.  Stroke 33(6):1706-1711, 2002.

Mark, K.S. and T.P. Davis.  Cerebral microvascular changes in permeability and tight junctions induced by hypoxia- reoxygenation.  American J. Physiology-Heart and Circulatory Physiology 282(4):H1485-H1494, 2002.

Abbruscato, T.J., K.S. Mark, B. Hawkins and T.P. Davis. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of Z0-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91(12):2525-2538, 2002.

Huber, J.D., R.D. Egleton and T.P. Davis.  Molecular physiology and pathophysiology of blood-brain barrier tight junction.  Trends in the Neurosciences 24(12):719-725, 2001.

Witt, K.A., J.D. Huber, R.D. Egleton, M.J. Roberts, M.D. Bentley, L. Guo, H. Wei, H.I. Yamamura and T.P. Davis.  Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to Met-enkephalin analogue DPDPE.  J. Pharmacol. Exp. Therap. 298(2):848-856, 2001.

Witt, K.A., T.J. Gillespie, R.D. Egleton, J.D. Huber and T.P. Davis.  Peptide drug modification to enhance bioavailability and blood brain barrier permeability.  Peptides 22:2329-2243, 2001.

Hom, S, R.D. Egleton, T.J. Abbruscato and T.P. Davis.  Effect of reduced flow on blood-brain barrier transport systems.  Brain Research 890(1):38-48, 2001.

Egleton, R.D., S.A. Mitchell, J. Huber, M.M. Palian, R. Polt, and T.P. Davis.  Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation.  J. Pharmacol. Exp. Therap. 299(3):967-972, 2001.

Moody, T.W., J. Chiles, M. Casibang, E.L. Moody, D. Chan and T.P. Davis. SR48692 is a neurotensin receptor agonist which inhibits the growth of small cell lung cancer cells.  Peptides 22:109-115, 2001.

Huber, J.D., K.A. Witt, S. Hom, R.D. Egleton, K.S. Mark, and T.P. Davis. Inflammatory pain alters blood brain barrier permeability and tight junctional protein expression.  American. J. Physiology-Heart and Circulatory Physiology. 280:H1241-H1248, 2001.

Witt, K.A., R.D. Egleton, J.D. Huber and T.P. Davis. Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect.  J. Pharmacol. Exp. Therap. 295(3):972-978, 2000.

Mark, K.S., and T.P. Davis.  Stroke: Development, prevention and treatment with peptidase inhibitors.  Peptides 21(12):1965-1973, 2000.

Bilsky, E.J., R.D. Egleton, J.D. Huber, H. Jones, H.I. Yamamura, J. Janders, T.P. Davis, P. Davis, F. Porreca, V.J. Hruby, S.A. Mitchell, M.M. Palian, R. Polt.  Enkephalin glycopeptide analogs produce analgesia with reduced dependence liability.  J. Med. Chem. 43(13):2586-2590, 2000.

Witt, K.A., R.D. Egleton, C. Slate, V.J. Hruby, and T.P. Davis.  Assessment of stereoselectivity of trimethylphenylalanine analogs of δ-opioid [D-Pen2, D-Pen5]-enkephalin.  J. Neurochemistry 75(1):424-435, 2000.

Egleton, R.D., S.A. Mitchell, R. Polt, V.J. Hruby, J.D. Huber and T.P. Davis.  Improved bioavailability to the brain of glycosylated Met-enkephalin analogs.  Brain Research 881(1):37-46, 2000.

Newcomb, R., T. Abbruscato, T. Singh, L. Nadasdi, T. P. Davis and G. Miljanich.  Bioavailability of ziconotide in brain: Influx from blood, stability and diffusion.  Peptides 21:491-501, 2000.

Rounseville, M., and T.P. Davis.  Prohormone convertase and autocrine growth factor mRNAs are coexpressed in small cell lung carcinoma.  J Molecular Endocrinology 25(1):121-128, 2000.

Abbruscato, T.J. and T.P. Davis.  Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: Influence of astrocyte contact.  Brain Research 842(2):277-286, 1999.

Gentry, C.L., R.D. Egleton, T. Gillespie and T.P. Davis.  The effect of halogenation on blood-brain barrier permeability of a novel peptide drug.  Peptides 20(10):1229-1238, 1999.

Rao, R.K., O. Koldovsky, C. Williams and T.P. Davis.  Milk inhibits somatostatin degradation in suckling rat jejunum in vivo.  J. Pediatric Gastroenterology and Nutrition, 28(1):84-94, 1999.

Egleton, R.D. and T.P. Davis.  Transport of the opioid receptor agonist [D-Pen2, D-Pen5]enkephalin across the blood-brain barrier involves transcytosis.  J. Pharm. Sci., 88(4):392-397, 1999.

Abbruscato, T.J. and T.P. Davis.  Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity.  J. Pharmacol. Exp. Ther. 289(2):668-675, 1999.

Kline, J.P., I. Bell, G.E. Schwartz, V. Hau and T.P. Davis.  Repressive and defensive coping styles predict resting plasma endorphin levels in the elderly.  Biological Psychology 49:295-302, 1998.

Egleton, R.D., Abbruscato, T.J., S. Williams, and T.P. Davis.  Transport of opioid peptides into the central nervous system.  J. Pharm. Sci. 87(11):1433-1439, 1998.

Gillespie, T, J. Erenberg, J.E. Taylor, S. Kim, J. Dong, V. Hau and T.P. Davis.  Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution.  J. Pharmacol. Exp. Ther. 285(1):95-104, 1998.

Li, G., W. Haq, L. Xiang, B.-S. Lou, R. Hughes, I.A. DeLeon, P. Davis, T.J. Gillespie, M. Romanowski, X. Zhu, A. Misicka, A.W. Lipkowski, F. Porreca, T.P. Davis, H.I. Yamamura, D.F. O’Brien and V.J. Hruby.  Modifications of the 4,4'-residues and SAR Studies of Biphalin, a highly potent opioid receptor active peptide.  Bioorganic & Medicinal Chemistry Letters 8(5):555-560, 1998.

Slaninova, J., Appleyard, S., A. Misicka, A.W. Lipkowski, T. Abbruscato, T.P. Davis, V.J. Hruby and H.I. Yamamura.  (125I-Tyr1) Biphalin binding to opioid receptors of rat brain and NG 108-15 cell membranes.  Life Sciences 62, 14: PL199-PL204, 1998.

Moody, T.W., Mayr, C.A., T. Gillespie and T.P. Davis.  Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines.  Peptides 19(2):253-258, 1998.

Egleton, R.D. and T.P. Davis.  Bioavailability and transport of peptides and peptide drugs into the brain.  Peptides 18(9):1431-1439, 1997.

Bell, I.R., G.E. Schwartz, R.R. Bootzin, V. Hau and T.P. Davis.  Elevation of plasma beta-endorphin levels of shy elderly in response to novel laboratory experiences.  Behavioral Medicine 22(4):168-173, 1997.

Waters, S.M., M.P. Rounseville and T.P. Davis.  Effect of dopaminergic drugs on processing and degradative neuropeptidase mRNA in rat frontal cortex and caudate-putamen.  Brain Research 754:28-34, 1997.

Thomas, S.A., T.J. Abbruscato, V.S. Hau, V.J. Hruby and T.P. Davis.  Structure-activity relationships of a series of [D-ALA2] deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability1.  J. Pharmacol. Exp. Ther. 281(2):817-825, 1997.

Abbruscato, T.J., S.A. Williams, V.J. Hruby and T.P. Davis.  Brain and spinal cord distribution of biphalin, correlation with opioid receptor density and mechanism of CNS entry.  J. Neurochemistry 69(3):1236-1245, 1997.

Thomas, S.A., T.A. Abbruscato, V.J. Hruby, and T.P. Davis.  The entry of [D-Penicillamine2,5] enkephalin into the central nervous system: Saturation kinetics and specificity.  J. Pharmacol. Exp. Ther. 280(3):1235-1240, 1997.

Abbruscato, T.J., S.A. Williams, V.J. Hruby, and T.P. Davis.  Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: Comparison with morphine.  J. Pharmacol. Exp. Ther.  280(1):402-409, 1997.

Moreau, J.-P., S. Kim, J.Z. Dong, F. Ignatious, S. Jackson, S.C. Moreau, B.A. Morgan, F. Touraud, J.E. Taylor, B. Tissier, M. Pellet, W. Murphy, and T.P. Davis.  Improved analogs and novel delivery systems for somatostatin octapeptides.  Metabolism, Vol. 45, No. 8, Suppl. 1, pp 24-26, 1996.

Konkoy, C.S. and T.P. Davis.  Ectoenzymes as sites of peptide regulation.  Trends in Pharmacological Sciences 17(8):288-294, 1996. (Review)

Waters, S., Konkoy, C.S. and T.P. Davis.  Haloperidol and Apomorphine differentially affect neuropeptidase activity.  J. Pharmacol. Exp. Ther. 277:113-120, 1996.

Greene, D.L., V.S. Hau, A. Misicka, R. Lipkowski, T. Abbruscato, T. Gillespie, V. J. Hruby and T.P. Davis.  Enkephalin analog pro-drugs: An assessment of in vitro  conversion, enzyme cleavage characterization and blood-brain barrier permeability.  J. Pharmacol. Exp. Ther. 277:1366-1375, 1996.

Abbruscato, T.J., S.A. Williams, V.J. Hruby and T.P. Davis.  Blood-to-CNS entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives.  J. Pharmacol. Exp. Ther. 276:1049-1057, 1996.

Konkoy, C.S., S.M. Waters and T.P. Davis.  Subchronic haloperidol administration decreases aminopeptidase N activity and met-enkephalin metabolism in rat striatum and cortex.  European J. Pharmacol. 297:47-51, 1996.

Bell, I.R., G.E. Schwartz, R.R. Bootzin, V. Hau, and T.P. Davis.  Time-dependent sensitization of plasma beta-endorphin in community elderly with self-reported environmental chemical odor intolerance.  Biological Psychiatry 40:134-143, 1996.        

Williams, S., T.S. Abbruscato, V.J. Hruby, and T.P. Davis.  The passage of a delta opioid receptor selective enkephalin, DPDPE, across the blood-brain and blood CSF barriers.  J. Neurochemistry 66:1289-1299, 1996.

Mania-Farnell, B.L., I. Botros, R. Day, and T.P. Davis.  Differential modulation of prohormone convertase mRNA by second messenger activators in two cholecystokinin producing cell lines.  Peptides 17:47-54, 1996.       

Rao, R.K., M Shantaon, S. Levenson, A. Raja, T.P. Davis, and A. Rao.  Molecular variants of epidermal growth factor in malignant astrocytoma.  Peptides 17(1):179-181, 1996.       

Hruby, V.J., N. Collins, F.-D. Lung, J.-P. Meyer, T.P. Davis, H.I. Yamamura and F. Porreca.  Design of peptides and peptidomimetics for delta and kappa opioid receptor subtypes.  Regulatory Peptides 54:123-124, 1995.

Hruby, V.J., T.P. Davis, R. Polt, F. Porreca, D. O’Brien, H.I. Yamamura, H. Bartosz, L. Szabo, T.J. Gillespie, A. Misicka, A. Lipkowski, X. Qian, G. Li, D. Patel and G. Bonner.  Design and synthesis of peptide ligands with unique biochemical and biological profiles at opioid receptors that cross the blood brain barrier.  Analgesia 1:469-472, 1995.

Mania-Farnell, B.L., I. Botros, and T.P. Davis.  Modulation of CCK mRNA in cell lines in response to isoproteranol and retinoic acid.  Neuropeptides 29:221-227, 1995.

Meyer, J.-P., T.J. Gillespie, V.J. Hruby, and T.P. Davis.  In vitro stability of some reduced peptide bond pseudopeptide analogs of dynorphin A. Peptides 16(7):1215-1219, 1995.

Konkoy, C.S. and T.P. Davis.  Regional metabolism of met-enkephalin and CCK on intact rat brain slices:  Characterization of specific peptidases.  J. Neurochemistry. 65(1):2773-2782, 1995.

Waters, S.M., and T.P. Davis.  Alterations of substance P metabolism and neuropeptidases in Alzheimer's disease.  J. Gerontology 50A: B315-B319, 1995.

Schetz, J.A., C. Mayr, J.-P. Moreau, J. Taylor, and T.P. Davis.  Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone related protein in the rat.  J. Pharmacol. Exp. Ther. 274(3):1456-1462, 1995.

Waters, S.M., C. Konkoy and T.P. Davis.  Neuropeptide metabolism on intact, regional brain slices: Effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.  J. Pharmacol. Exp. Ther. 274: 783-789, 1995.

Slaninova, J., R.J. Knapp, S.J. Weber, T.P. Davis, S.N. Fang, V.J. Hruby,  H.I. Yamamura.  [125I]SNF-8702: A selective radioligand for cholecystokinin B receptors.  Peptides 16(2):221-224, 1995.

Hruby, V.J., A. Misicka, A.W. Lipkowski, R.C. Haaseth, H. Bartosz-Beechowski, X. Qian, N. Collins, J.P. Meyer, L. Szabo, R. Polt, F. Porreca, T.P. Davis and H.I. Yamamura.  New opioid compounds in analgesia.  Regulatory Peptides S71-S72, 1994.

Mania-Farnell, B.L., B.J. Merrill, H.I. Yamamura and T.P. Davis.  Second messenger activators regulate CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC.  Annals of the New York Academy of Sciences 713:446-449, 1994.

Haaseth, R.C., P.J. Horan, E.J. Bilsky, T.P. Davis, T. Zalewska, J. Slaninova, H.I. Yamamura, S. Weber, T.P. Davis, F. Porreca and V.J. Hruby. [L-Ala3] DPDPE: A new enkephalin analog with a unique opioid receptor activity profile.  Further evidence of delta opioid receptor multiplicity.  J. Medicinal Chemistry 37:1572-1577, 1994.       

Brownson, E.A., T.J. Abbruscato, T.J. Gillespie and T.P. Davis.  Effect of peptidases at the blood brain barrier on the permeability of enkephalins.  J. Pharmacol. Exp. Ther. 270(2):675-680, 1994.       

Konkoy, C.S., S.M. Waters and T.P. Davis. Acute administration of neuroleptics decreases neurotensin metabolism on intact regional rat brain slices.  J. Pharmacol. Exp. Ther. 269(2):555-563, 1994.

Polt, R., Porreca, F., Lajos Z.S., Bilsky, E.J., Davis, T.P., Davis, T.P., Horvath, R., McCormick, J.M., Yamamura, H., Hruby, V. Glycopeptide enkephalin analogues cross the blood-brain barrier in vivo to produce analgesia in mice.  Proc. Nat. Acad. Sci. USA 91:7114-7118, 1994.

Oakes, M.G., and T.P. Davis.  The ontogeny of enzymes involved in the post-translational processing and metabolism of neuropeptides.  Developmental Brain Research 80:127-136, 1994.

Quay T., Slaughter C., Davis T.P., Merrill B.J., Hersh L.B.  Positional effects in the neutral endopeptidase (enkephalinase) reaction.  Archives in Biochemistry and Biophysics 308(1):133-136, 1994.

Rao, R.K., H.-H. Chang, S. Levenson, F. Porreca, P. Brannon, T.P. Davis, and O. Koldovsky.  Ontogenic differences in the inhibition of gastric acid secretion by epidermal growth factor.  J. Pharmacol. Exp. Therap. 266(2):647-654, 1993.

Mania-Farnell, B., P.N.M. Konings, B. Merrill, and T.P. Davis.  Differential regulation of  CCKmRNA in the human neuroblastoma cell line SK-N-MC-9c in response to second  messenger activators.  FEBS Letters 335(1):65-68, 1993.

Horan, P., A. Mattia, E.J. Bilsky, S. Weber, T.P. Davis, V.J. Hruby, and F. Porreca.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.  J. Pharmacol. Exp. Ther. 265:1446-1454, 1993.

Clark, D.A., R. Day, N. Seidah, T.W. Moody, F. Cuttitta and T.P. Davis. Protease inhibitors suppress in vitro growth of human small cell lung cancer.  Peptides 14:1021-1028, 1993.

Horan, P.J., K.D. Wild, A. Misicka, A. Lipkowski, V.J. Hruby, S.J. Weber, T.P. Davis, H.I. Yamamura and F. Porreca.  Agonist and Antagonist Profiles of (D-Ala2, Glu4) Deltorphin and its (Cys4) - and (Ser4) Derivatives:  Further evidence of opioid delta receptor multiplicity.  J. Pharmacol. Exp. Ther. 265:896-902, 1993.

Weber, S.J., T.J. Abbruscato, V.J. Hruby, H.I. Yamamura and T.P. Davis.  Assessment of an in vitro Blood-Brain Barrier model using several [met]5 enkephalin opioid analogs.  J. Pharmacol. Exp. Ther. 266:1649-1655, 1993.

Konings, P.N.M., Farnell, B., M.C. Beinfeld, B.J. Merrill, T.W. Moody, R. Day, N.G. Seidah, and T.P. Davis.  Processing, release and metabolism of cholecystokinin in SK-N-MC1XC cells. Neuropeptides 25:19-30, 1993.

Konkoy, C., M.J. Oakes, and T.P. Davis. Chronic treatment with neuroleptics alters neutral endopeptidase 24.11 activity in rat brain regions. Peptides 14:1017-1020, 1993.

Horan, P., W. Kazmierski, R. Ferguson, V.J. Hruby, S. Weber, T.P. Davis, L. Fang, R. Knapp, H.I. Yamamura, T. Kramer, T.F. Burks and F. Porreca.  Unexpected antinociceptive potency of cyclic [D-Tca1]-CTAP:  Potential for a novel mechanism of action. Eur. J. Pharmacol. 233:53-62,1993.

Rao, R.K., O. Koldovsky and T.P. Davis.  Fate of intraduodenally administered somatostatin in rats in vivoPeptides 14(6):1199-1203, 1993.

Fang L., Knapp R.J., Matsunaga T., Weber S., T.P. Davis, Hruby V., Yamamura H.I. Synthesis of [4'-125I-Phe3,Glu4]deltorphin and characterization of its delta opioid receptor binding properties.  Life Sciences 51:189-193, 1992.

Banks, W.A., K.L. Audus and T.P. Davis.  Permeability of the Blood-Brain Barrier to Peptides: An Approach to the Development of Therapeutically Useful Analogs.  Peptides 13:1289-1294, 1992.

Gillespie, T.J., P.N.M. Konings, B. Merrill and T.P. Davis.  A specific enzyme assay for aminopeptidase M. in rat brain.  Life Sciences 51(26):2097-2106, 1992.

Weber, S.J., D.L. Greene, V.J. Hruby, H.I. Yamamura, F. Porreca and T.P. Davis. Whole body and brain distribution of [3H] DPDPE after I.P., I.V., P.O., and S.C. administration.  J. Pharmacol. Exp. Ther. 263(3):1308-1316, 1992.

Davis, T.P., S. Crowell, J. Taylor, J.P. Moreau, D. Coy, J. Staley and T.W. Moody.  Metabolic Stability and tumor inhibition of Bombesin/GRP receptor antagonists.  Peptides 13:401-407, 1992.

Weber, S., L. Trombley, P. Davis and T.P. Davis.  Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease.  J. Gerontology 47(1):B18-B25, 1992.

Davis, T.P., T.J. Gillespie and P.N.M. Konings.  Specificity of neurotensin metabolism by regional rat brain slices.  J. Neurochemistry 58:608-617, 1992.

Weber, S.J., S. Sharma, G. Toth, L. Hersh, V. Hruby, D. Greene, H.I. Yamamura and T.P. Davis.  Distribution and analgesia of [D-Pen2,D-Pen5] enkephalin and two halogenated analogues following intravenous administration.  J. Pharmacol. Exp. Ther. 259(3):1109-1117, 1991.

Rao, R.K., O. Koldovsky and T.P. Davis.  Regional differences in the gastrointestinal processing of epidermal growth factor in suckling rats.  American J. Physiol. 261:G790-G798, 1991.

Knapp, R.J., S. Sharma, G. Toth, M. Duong, C. Bogert, T.P. Davis, V. Hruby and H.I. Yamamura.  [D-Pen2,4 I-Phe4,D-Pen5]enkephalin:  A  selective and high affinity radioligand for delta opioid receptors with exceptional specific activity.  J. Pharmacol. Exp. Ther. 258(3):1077-1083, 1991.

Davis, T.P., T. Gillespie, J. Shook, K. Hawkins, P. Davis, H.I. Yamamura and T.F. Burks.  Changes in opioid receptor selectivity following processing of peptide E:  Effect on gut motility.  Gastroenterology 100:1603-1615, 1991.

Davis, T.P., S. Crowell, B. McInturff, R. Louis and T. Gillespie.  Neurotensin may function as a regulatory peptide in small cell lung cancer.  Peptides 12:17-23, 1991.

Konings, P., A.J. Culling-Berglund and T.P. Davis.  Chronic haloperidol and chlorpromazine treatment alters in vitro β-endorphin metabolism in rat brain.  Eur. J. Pharmacol. 191:115-128, 1990.

Davis, T.P., G. Hoyer, P. Davis and T.F. Burks. Proenkephalin A derived peptide E and its fragments alter opioid contractility in the small intestine. Eur. J. Pharmacol. 191:253-261, 1990.

Davis, T.P., B. McInturff, T.W. Moody and S.L. Crowell.  Protease inhibitors suppress in vitro clonal growth of human small cell lung cancer.  Eur. J. Pharmacol. 183(2):194-195, 1990.

Morrill, M., R. Louis and T.P. Davis.  Haloperidol, chlorpromazine and apomorphine alter central regional neuropeptidase activity.  Eur. J. Pharmacol. 183(6):2318-2319, 1990.

Li, Z.W., K. Brendel, J. Van Nispen and T.P. Davis.  Neuropeptide processing in regional brain slices:  Effect of conformation and sequence.  J. Pharmacol. Exp. Ther. 253(2):851-857, 1990.

Newcomb, S.A., A.J. Culling-Berglund and T.P. Davis.  Endogenous levels of carotenoids in human buccal mucosa cells by RP-HPLC.  J. Chromatography 526(1):47-58, 1990.

Rao, R.K., O. Koldovsky and T.P. Davis.  Inhibition of intestinal degradation of somatostatin by rat milk.  American J. Physiology. 258:G426-G431, 1990.       

Rao, R.K., O. Koldovsky, P.F. Pollack, M. Korc, S. Wright and T.P. Davis.  Processing and transfer of epidermal growth factor in developing rat jejunum and ileum.  Peptides 11(6):1093-1102, 1990.

Crowell, S.L., H.S. Burgess and T.P. Davis.  Effect of mycoplasma on the autocrine stimulation of human small cell lung cancer in vitro by bombesin and β-endorphin.  Life Sciences 45:2471-2476, 1989.

Davis, T.P., T.J. Gillespie and F. Porreca.  Peptide fragments derived from the β-chain of hemoglobin (hermorphins) are centrally active in vivoPeptides 10:747-751, 1989.

Staley, J., G. Fiskum, T.P. Davis, and T.W. Moody.  Neurotensin elevates cytosolic calcium in small cell lung cancer cells.  Peptides 10:1217-1221, 1989.       

Davis, T.P., T.W. Moody, R. Liu, S. Crowell and H. Burgess.  β-endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells.  Eur. J. Pharmacol. 161:283-285, 1989.

Plezia, P.M., D.S. Alberts, Y.M. Peng, M.J. Xu, S. Sayers, T.P. Davis, E.A. Surwit and F.L. Meyskens.  The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention studies.  Preventive Medicine 18:680-687, 1989       

Culling-Berglund, A.J., S.A. Newcomb, M. Gagne, W.S. Morfitt and T.P. Davis.  A sensitive and specific procedure for the analysis of β-carotene in human skin.  J. Micronutrient Analysis 5:139-148, 1989.

Carrier, M., D.H. Russell, T.P. Davis, R.W. Emery and J.G. Copeland.  Value of urinary polyamines as noninvasive markers of cardiac allograft rejection in the dog.  Ann. Thorac. Surg. 45:158-163, 1988.

Margolis, S.A., and T.P. Davis.  Stabilization of ascorbic acid in human plasma, and its liquid-chromatographic measurement.  Clinical Chemistry 34:2217-2223, 1988.

Carrier, M., D.H. Russell, T.P. Davis, R.W. Emery and J.G. Copeland.  Urinary polyamines as markers of cardiac allograft rejection.  J. Thoracic Cardiovasc. Surgery 96(5):806-810, 1988.

Belyea, R.L., F.A. Martz, M. Madhisetty and T.P. Davis.  Intake, digestibility and energy utilization of corrugated paper diets.  Animal Feed Sci. and Tech. 17:57-64, 1987.

Carrier, M., J.G. Copeland, D.H. Russell, M.J. Perrotta, T.P. Davis and R.W. Emery.  Urinary polyamines are non-invasive markers of cardiac allograft rejection.  J. Heart Transplantation 6:286-289, 1987.

Conrad, K.A., T.C. Fagan, P. May Shar, T.P. Davis and D.G. Johnson.  Anti-hypertensive effects of parenteral nicardipine alone and with captopril. Clin. Pharm. and Therap. 42(1):113-118, 1987.

Davis, T.P. and A.J. Culling-Berglund.  Neuroleptic drug treatment alters in vitro central neurotensin metabolism. Psychoneuroendocrinology 12(4):253-260, 1987.

Davis, T.P., A.J. Culling-Berglund, T.J. Gillespie and T.L. Smith. Ethanol treatment alters β-endorphin metabolism by purified synaptosomal membranes.  Peptides 8:467-472, 1987.

Davis, T.P., A.J. Culling-Berglund and H. Schoemaker.  Specific regional differences of β-endorphin metabolism in schizophrenics.  Life Sciences 39(26):2601-2609, 1986.

Davis, T.P., T.J. Gillespie, R. Yekta, and T.M. Hansen. Chromatographic characterization of nutritional components in a low calorie, juice based beverage.  Flussiges Obst. 11:577-580, 1986.

Davis, T.P., A. Han, and M.K. Yousef.  Central metabolism of β-endorphin in different species of temperature acclimated rodents.  Comp. Biochem. Physiol. 84c(1):105-111, 1986.

Hameroff, S.R., R.C. Cork, J.L. Weiss, B.R. Crago, and T.P. Davis.  Doxepin effects on chronic pain and depression:  A controlled study.  Clin. J. of Pain 1:171-176, 1985.

Dray, A., and T.P. Davis.  The Proenkephalin A fragment metorphamide shows supraspinal and spinal opioid activity in vivoPeptides 6:217-221,1985.

Davis, T.P. and A.J. Culling-Berglund.  High performance liquid chromatographic analysis of in vitro central neuropeptide processing.  J. Chromatography 327:279-292, 1985.

Davis, T.P., Porreca, F., T.F. Burks, and A. Dray.  The Proenkephalin A fragment peptide E:  Central processing and in vivo CNS activity.  European J. Pharmacology 111:177-184, 1985.

Peng, Y.-M., D.S. Alberts, and T.P. DavisIn vivo and in vitro metabolism of the new anticancer drug bisantrene.  Cancer Chemotherapy and Pharmacology 14:15-20, 1985.

Alberts, D.S., Y.M. Peng, S. Leigh, T.P. Davis, and D.L. Woodward.  Disposition of Mitoxantrane in cancer patients.  Cancer Research 46:1879-1884, 1985.